Human Serum Matrix for IVD Calibrators & Controls — IVDR Requirements

One of the most frequently raised issues in EU IVDR technical file reviews is matrix matching — specifically, whether the human serum matrix used for calibrators and controls is genuinely appropriate for the intended analytical system. Here is what matrix matching means in practice, why it matters and how to choose the right serum format.

What Matrix Matching Means Under EU IVDR

EU IVDR 2017/746, Annex I (General Safety and Performance Requirements) requires that IVD devices achieve the performance claimed by the manufacturer under the intended conditions of use. For quantitative assays, this means that calibrators and quality controls must produce results traceable to the same reference method used for patient samples — and that the matrix of the calibrator and control material must not introduce systematic bias vs. the patient sample matrix.

A matrix effect occurs when something in the calibrator matrix — other than the target analyte — affects the assay signal differently than it does in clinical patient samples. Classic examples:

• Calibrator prepared in BSA-buffer instead of human serum — different viscosity, protein binding and surface interactions produce a different calibration curve shape
• Calibrator in US-origin plasma vs. patient samples in EU pooled serum — different complement activity and protein glycosylation patterns can shift immunoassay signal
• Calibrator in neat serum vs. patient samples from anti-coagulated plasma — fibrinogen presence in plasma changes assay kinetics in some systems

Selecting the Right Human Serum Format by Assay Type

Why EU Donor Origin Matters for IVDR Submissions

A frequently overlooked aspect of IVDR technical file preparation is the documentation of raw material origin for human matrix materials. Notified bodies increasingly ask manufacturers to justify the use of non-EU source material in CE-marked IVD products intended for the EU market.

The rationale is straightforward: EU Blood Directive 2002/98/EC sets quality and safety standards for human blood and blood components. Using EU-qualified donor material processed under this framework gives your technical file the clearest regulatory basis. Donor screening panels, processing standards and traceability requirements are all aligned with EU requirements by default.

US-origin material is not excluded — but it requires explicit documentation that the material meets equivalent safety standards, which adds regulatory burden without providing any quality advantage for EU-market products.

Lot Reservation for IVD Production Continuity

IVD products have multi-year market lifecycles. A calibrator or control that passes validation with one serum lot must maintain its performance claim over the entire product lifecycle — which means you either need to reserve a sufficient quantity of your validated lot, or run full comparability studies every time you change lots.

For high-volume IVD production, lot reservation is the only practical approach. The key is to calculate correctly: annual serum consumption × product lifecycle years × 1.5 safety factor = reservation volume. This is often larger than teams initially estimate — see our batch reservation calculator for guidance.